• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 1, 2018

View Archived Issues

Madrigal's stock soars as promising midstage trial readout intensifies NASH race

Shares of Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) rocketed 145 percent higher to $265.61 Thursday on top-line 36-week phase II nonalcoholic steatohepatitis (NASH) data for MGL-3196. The drug showed statistically significant benefits in relative reduction of liver fat, the trial's primary endpoint, and NASH resolution, an accepted FDA regulatory endpoint, fueling new interest in the company's bid to conquer the obesity-linked condition for which no medicines are currently approved. Read More

REMS guidances intended to speed competition to market

In releasing two draft guidances Thursday on shared risk evaluation and mitigation strategies (REMS), the FDA took aim at another shenanigan some brand drug companies have used to delay competition. The guidances, which discuss the development of a shared system REMS and waivers for the single, shared REMS requirement, are being touted as a way to enhance competition, one of the pillars in the administration's recently announced blueprint to reduce drug prices.  Read More

CAMP4 raises $30M series A to elevate gene circuitry platform

CAMP4 Therapeutics is on a mission to modernize drug discovery and development, and the Cambridge, Mass.-based company just scored a $30 million series A to climb toward that goal. Read More

Nektar NDA for NKTR-181 seeks precise path across troubled opioid landscape

Following last year's phase III win in the SUMMIT-07 study of NKTR-181 in more than 600 patients with moderate to severe chronic low back pain, Nektar Therapeutics Inc. took the next step toward commercialization by submitting the new drug application (NDA) to the FDA. The San Francisco-based company is seeking to advance the mu-opioid agonist, which has shown reduced incidence of central nervous system-mediated side effects such as euphoria, along the road less traveled to set itself apart in the controversial asset class. If approved, NKTR-181 could become the first analgesic opioid molecule to exhibit reduced incidence of such effects, through targeted alteration of brain-entry kinetics. Read More

Multitasking nanorobot fights bacterium and its toxin

Multiple nanorobots with single functions have been developed in recent years. Now, researchers have created a single nanorobot with multiple functions. Read More

Luye expanding I-O deal with U.S. firm Elpis to focus on CAR T therapies

HONG KONG – China's Luye Pharma Group Ltd. has partnered up with U.S. biotech firm Elpis Biopharmaceuticals Corp. to work on dual target-based therapies for cancer patients who fail to respond to current treatment. Read More

Shoes, 'Stones' and surfing: BioWorld's 12th annual Summer Reading List

Summer arrives with a bang for biopharma in the dueling agendas of the American Society of Clinical Oncology (ASCO) annual meeting, the BIO International Convention, Digestive Disease Week (DDW) and ASM Microbe – all packed into a 12-day period – not to mention overlapping health care conferences sponsored by several major investment banks. What's a harried insider to do? Breathe deeply, then take a gander at BioWorld's 12th annual Summer Reading List before you head to the airport for 10 days of sleep deprivation and jet lag. As always, our staff and readers from across the industry have you covered. Read More

Financings

Sisaf Ltd., of London, closed a $4.3 million interim funding round led by Vickers Venture Partners with additional capital contributions by Invest NI and Innovation Ulster Ltd. The company plans to use the investment to accelerate the development of its dermatology pipeline. Read More

Other news to note

Contravir Pharmaceuticals Inc., of Edison, N.J., reported findings from a preclinical study of CRV-431 indicating that the drug, a cyclophilin inhibitor, decreased the extent of fibrosis in an animal model by 46 percent compared to vehicle control.  Read More

Regulatory front

The Pharmaceutical Research and Manufacturers of America (PhRMA) responded to an analysis comparing assessments by the Institute for Clinical and Economic Review's (ICER), warning that a one-size-fits-all framework would mean that 62 percent to 93 percent of patients with serious, complex conditions would face access barriers to treatment.  Read More

Clinical data for May 31, 2018

Read More

Regulatory actions for May 31, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe